RT Journal Article
SR Electronic
T1 Plasma Markers of Disrupted Gut Permeability in Severe COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.13.20231209
DO 10.1101/2020.11.13.20231209
A1 Giron, Leila B.
A1 Dweep, Harsh
A1 Yin, Xiangfan
A1 Wang, Han
A1 Damra, Mohammad
A1 Goldman, Aaron R.
A1 Gorman, Nicole
A1 Palmer, Clovis S.
A1 Tang, Hsin-Yao
A1 Shaikh, Maliha W.
A1 Forsyth, Christopher B.
A1 Balk, Robert A.
A1 Zilberstein, Netanel F
A1 Liu, Qin
A1 Kossenkov, Andrew
A1 Keshavarzian, Ali
A1 Landay, Alan
A1 Abdel-Mohsen, Mohamed
YR 2021
UL http://medrxiv.org/content/early/2021/05/15/2020.11.13.20231209.abstract
AB A disruption of the crosstalk between the gut and the lung has been implicated as a driver of severity during respiratory-related diseases. Lung injury causes systemic inflammation, which disrupts gut barrier integrity, increasing the permeability to gut microbes and their products. This exacerbates inflammation, resulting in positive feedback. We aimed to test whether severe Coronavirus disease 2019 (COVID-19) is associated with markers of disrupted gut permeability. We applied a multi-omic systems biology approach to analyze plasma samples from COVID-19 patients with varying disease severity and SARS-CoV-2 negative controls. We investigated the potential links between plasma markers of gut barrier integrity, microbial translocation, systemic inflammation, metabolome, lipidome, and glycome, and COVID-19 severity. We found that severe COVID-19 is associated with high levels of markers of tight junction permeability and translocation of bacterial and fungal products into the blood. These markers of disrupted intestinal barrier integrity and microbial translocation correlate strongly with higher levels of markers of systemic inflammation and immune activation, lower levels of markers of intestinal function, disrupted plasma metabolome and glycome, and higher mortality rate. Our study highlights an underappreciated factor with significant clinical implications, disruption in gut functions, as a potential force that may contribute to COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is supported by a supplement to the NIH R01 DK123733 (R01 DK123733-01S1) for M.A-M, A.L, and A.Ke and R24 AA026801- 02S1 for A.Ke. M.A-M is also supported by The Foundation for AIDS Research (amfAR) impact grant # 109840-65-RGR, NIH grants (R01 AG062383, R01NS117458, R21 AI143385, R21 AI129636, and R21 NS106970), and the Penn Center for AIDS Research (P30 AI 045008). The Wistar Proteomics and Metabolomics Shared Resource is supported in part by NIH Cancer Center Support Grant CA010815. The Thermo Q-Exactive HF-X mass spectrometer was purchased with NIH grant S10 OD023586. We would like to thank Rachel E. Locke, Ph.D., for providing comments.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics. All research protocols of the study were approved by the institutional review board (IRB) at Rush University (20070905-IRB01; approved July-27-2020). All human experimentation was conducted in accordance with the guidelines of the US Department of Health and Human Services and those of the authors institutions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript or upon request.